Clinical Trial Update: Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer. [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial from the University of Chicago is evaluating outcomes of combining darolutamide with androgen deprivation therapy in metastatic hormone…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Androgen deprivation therapy (Androgen deprivation therapy)
• Darolutamide (darolutamide)

Snippet

Sponsor: University of Chicago | Conditions: Prostate Cancer | Phase 4 | Status: NOT_YET_RECRUITING